Literature DB >> 17804124

Comparative efficacy of an indigenous 'inactivated vaccine' using highly pathogenic field strain of Mycobacterium avium subspecies paratuberculosis 'Bison type' with a commercial vaccine for the control of Capri-paratuberculosis in India.

S V Singh1, P K Singh, A V Singh, J S Sohal, V K Gupta, V S Vihan.   

Abstract

Johne's disease (JD) is endemic in goatherds located at Central Institute for Research on Goats, Makhdoom, since 1979 and lately it has been reported from farmer's herds in equal frequencies. Despite using test and slaughter method for the control of JD for more than 25 years in these herds, incidence of JD has not been reduced. Efficacy of 'indigenous vaccine' containing native 'Bison type' genotype of Mycobacterium avium subspecies paratuberculosis (MAP) was compared with commercial vaccine using challenge studies with homologous strain of MAP. Goat kids (85) were randomly divided in to three groups. Kids were vaccinated with 1 ml of vaccine subcutaneously and Sham-immunized with 1 ml of sterile PBS. All kids except 3 in each group were challenged twice at 75- and 275-day post-vaccination (DPV). Four goats each from three groups were sacrificed at 200-day post-challenge to evaluate carcass and histopathologically for vaccine and challenge response in kids of different groups. Samples (blood, serum and fecal) were screened for LTT, ELISA and shedding of bacilli and data on live animal traits, mortality and experimental sacrifice were compared. Average body weights gained by goats in three groups at different stages of trials (0, 1-75, 76-275, 276-425 DPV) showed marked improvements in performance of vaccinated groups over 'Sham-immunized' group. Effect of vaccines against challenge became visible in terms of body weights gained at 276-425 DPV ('Bison' group gained significantly higher body weights than 'Sham-immunized'). Mortality was significantly less in two vaccinated as compared to 'Sham-immunized'. Vaccinated groups also had significant stimulation and sero-conversion for cell mediated and humoral immune response, respectively as compared to 'Sham-immunized'. Results of post-challenged fecal culture showed significant reduction in shedding of MAP in both vaccinated groups than in 'Sham-immunized'. There was significant improvement in external and internal body traits and histological lesions in case of vaccinated than 'Sham-immunized' group.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804124     DOI: 10.1016/j.vaccine.2007.07.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Therapeutic Effects of a New "Indigenous Vaccine" Developed Using Novel Native "Indian Bison Type" Genotype of Mycobacterium avium Subspecies paratuberculosis for the Control of Clinical Johne's Disease in Naturally Infected Goatherds in India.

Authors:  S V Singh; P K Singh; A V Singh; J S Sohal; M C Sharma
Journal:  Vet Med Int       Date:  2010-02-14

2.  Efficacy of 'indigenous vaccine' using native 'Indian bison type' genotype of Mycobacterium avium subspecies paratuberculosis for the control of clinical Johne's disease in an organized goat herd.

Authors:  K Singh; B S Chandel; H C Chauhan; A Dadawala; S V Singh; P K Singh
Journal:  Vet Res Commun       Date:  2013-01-24       Impact factor: 2.459

3.  Assessment of live candidate vaccines for paratuberculosis in animal models and macrophages.

Authors:  Gabriella M Scandurra; Geoffrey W de Lisle; Sonia M Cavaignac; May Young; R Pamela Kawakami; Desmond M Collins
Journal:  Infect Immun       Date:  2009-12-28       Impact factor: 3.441

4.  Paratuberculosis control: a review with a focus on vaccination.

Authors:  Felix Bastida; Ramon A Juste
Journal:  J Immune Based Ther Vaccines       Date:  2011-10-31

5.  Application of IS1311 locus 2 PCR-REA assay for the specific detection of 'Bison type' Mycobacterium avium subspecies paratuberculosis isolates of Indian origin.

Authors:  Ajay Vir Singh; Devendra Singh Chauhan; Abhinendra Singh; Pravin Kumar Singh; Jagdip Singh Sohal; Shoor Vir Singh
Journal:  Indian J Med Res       Date:  2015-01       Impact factor: 2.375

Review 6.  Current status of Mycobacterium avium subspecies paratuberculosis infection in animals & humans in India: What needs to be done?

Authors:  Ajay Vir Singh; Devendra Singh Chauhan; Shoor Vir Singh; Vijay Kumar; Abhinendra Singh; Anjali Yadav; Virendra Singh Yadav
Journal:  Indian J Med Res       Date:  2016-11       Impact factor: 2.375

7.  Occurrence of Mycobacterium avium subspecies paratuberculosis across host species and European countries with evidence for transmission between wildlife and domestic ruminants.

Authors:  Karen Stevenson; Julio Alvarez; Douwe Bakker; Franck Biet; Lucia de Juan; Susan Denham; Zoi Dimareli; Karen Dohmann; Gerald F Gerlach; Ian Heron; Marketa Kopecna; Linda May; Ivo Pavlik; J Michael Sharp; Virginie C Thibault; Peter Willemsen; Ruth N Zadoks; Alastair Greig
Journal:  BMC Microbiol       Date:  2009-10-07       Impact factor: 3.605

8.  Genomic variations associated with attenuation in Mycobacterium avium subsp. paratuberculosis vaccine strains.

Authors:  Tim J Bull; Alex Schock; J Michael Sharp; Mandisa Greene; Iain J McKendrick; Jill Sales; Richard Linedale; Karen Stevenson
Journal:  BMC Microbiol       Date:  2013-01-22       Impact factor: 3.605

9.  Effects of vaccination against paratuberculosis on tuberculosis in goats: diagnostic interferences and cross-protection.

Authors:  Bernat Pérez de Val; Miquel Nofrarías; Sergio López-Soria; Joseba M Garrido; H Martin Vordermeier; Bernardo Villarreal-Ramos; Maite Martín; Eugenia Puentes; Ramón A Juste; Mariano Domingo
Journal:  BMC Vet Res       Date:  2012-10-16       Impact factor: 2.741

10.  A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis.

Authors:  Tim J Bull; Sarah C Gilbert; Saranya Sridhar; Richard Linedale; Nicola Dierkes; Karim Sidi-Boumedine; John Hermon-Taylor
Journal:  PLoS One       Date:  2007-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.